Your thyroid produces mostly T4, but tissues rely heavily on T3 to generate an active thyroid signal.
This creates an understandable concern when someone has:
The common explanation is:
“My thyroid makes enough T4, but my body cannot convert it into T3.”
T4-to-T3 conversion is real physiology.
But a clinical “conversion problem” is more difficult to establish than this statement suggests.
T3 availability depends on much more than one conversion enzyme. It is shaped by:
A low T3 result may reflect reduced conversion.
It may also represent an adaptive response to illness, under-eating, or another physiological stressor rather than a permanent defect requiring T3 treatment.
The useful question is not simply:
“How do I increase conversion?”
It is:
“Why is T3 availability low, and does the complete pattern support a thyroid-related explanation?”
Mutant evaluates cellular T3 activation within a broader thyroid model that also considers hormone supply, transport, cellular response, selenium and antioxidant context, thyroid-axis regulation, and other biological systems.
Mutant Free includes your top 3 ranked health hypotheses across your entire analysis in full.
The thyroid gland releases primarily thyroxine, or T4.
T4 acts partly as a circulating reservoir that tissues can convert into more active or inactive thyroid-hormone forms.
A simplified pathway is:
T4 ↓ Active T3
or:
T4 ↓ Inactive reverse T3
T3 then binds thyroid-hormone receptors and influences gene activity throughout the body.
Thyroid signaling contributes to:
Conversion is therefore not one switch that is either working or broken.
It is a regulated system that changes according to the body’s circumstances.
Deiodinases remove iodine atoms from thyroid hormones and help determine whether thyroid signaling is activated or reduced.
DIO1 is expressed primarily in tissues such as the:
It contributes to circulating T3 production and clearance of inactive thyroid-hormone metabolites.
DIO1 activity can be influenced by:
DIO2 helps generate T3 locally within specific tissues.
It is active in areas including:
DIO2 allows tissues to regulate some of their own local T3 availability rather than depending entirely on circulating T3.
This is one reason serum T3 does not necessarily describe every detail of thyroid signaling inside every tissue.
That does not mean symptoms can be used to diagnose hidden tissue hypothyroidism when routine thyroid testing is otherwise reassuring.
DIO3 reduces thyroid-hormone activity.
It converts:
DIO3 activity can increase during:
The final thyroid signal depends on the balance among:
Hormone supply + activation + inactivation + transport + receptor response
The phrase can refer to several different situations.
Peripheral T4-to-T3 activation may have fallen.
This can occur during:
Tissue-specific DIO2 activity may change without being perfectly represented by serum T3.
But there is no routine clinical test that directly measures T3 generation inside every tissue.
Illness or tissue stress can shift thyroid-hormone metabolism toward inactive pathways.
This can be part of non-thyroidal illness physiology rather than a permanent conversion defect.
Conversion cannot maintain T3 when there is inadequate T4 substrate.
Possible reasons include:
This is fundamentally a hormone-supply problem, not necessarily a conversion problem.
T4 and T3 depend on transport mechanisms to enter cells.
Transport biology may influence tissue exposure.
Common transporter variants do not establish clinically important intracellular thyroid deficiency.
Once thyroid hormone enters a cell, receptors and regulatory proteins help translate the signal into changes in gene activity.
Again, a genetic susceptibility in this layer does not prove that current symptoms result from impaired thyroid signaling.
Lower effective thyroid signaling can be associated with:
These symptoms are not specific to a conversion problem.
The same pattern can occur with:
Symptoms can justify investigation.
They cannot identify the mechanism by themselves.
Serious illness can alter thyroid-hormone metabolism without the thyroid gland itself failing.
This is often called:
A common pattern may involve:
Low T3 Normal or low TSH Normal or low-normal Free T4
During prolonged or severe illness, Free T4 may also decline.
Possible mechanisms include:
This can occur during:
The low T3 result is real.
But it does not automatically mean the person has primary hypothyroidism or needs liothyronine.
The underlying illness usually remains the more important clinical problem.
The body may reduce T3 availability when energy intake falls.
This can happen during:
Possible symptoms include:
A laboratory pattern may look like:
Normal TSH Normal Free T4 Low or low-normal T3
This may represent an energy-conservation response rather than permanent conversion failure.
Increasing T3 pharmacologically without correcting inadequate intake may change the laboratory number while leaving the larger problem unresolved.
T3 may fall in some people during very-low-carbohydrate diets, particularly when carbohydrate restriction also reduces total energy intake.
The clinical meaning varies.
A lower T3 result does not automatically indicate disease or tissue-level hormone deficiency.
Important questions include:
Carbohydrate intake should not be interpreted separately from overall energy intake, protein intake, weight trajectory, and health status.
The liver contributes to:
Liver disease can alter:
A low T3 result in someone with liver disease should not automatically be labeled a primary deiodinase defect.
The kidneys also participate in thyroid-hormone metabolism and clearance.
Chronic kidney disease can be associated with:
Again, low T3 may reflect systemic disease rather than an isolated conversion disorder.
Inflammatory signaling can influence:
This helps explain why T3 may decline during:
It does not mean every mildly elevated inflammatory marker creates clinically significant conversion failure.
Several medications can influence thyroid-hormone metabolism or laboratory results.
Depending on the medication, effects may include:
Examples can include certain:
The clinical importance depends on:
Do not stop prescribed medication because of a suspected conversion effect without discussing it with the prescribing clinician.
A person cannot maintain T3 production if too little T4 is available.
Possible causes include:
The pattern may involve low Free T4 rather than an isolated low T3.
Before focusing on conversion, confirm that adequate T4 substrate is available.
People taking levothyroxine may appear to have inadequate thyroid-hormone availability because the medication is not absorbed consistently.
Absorption can be affected by:
This is not technically a conversion problem.
It is a hormone-supply problem occurring before conversion.
Deiodinases are selenoproteins.
Significant selenium deficiency can impair thyroid-hormone metabolism.
That does not mean everyone with low T3 or a DIO variant should take selenium.
Supplementation may be unnecessary or harmful when:
Potential selenium toxicity can include:
The goal is adequate selenium—not the highest tolerated dose.
Thyroid-hormone production and metabolism occur within a redox-sensitive environment.
Selenoproteins and antioxidant systems help protect cells while supporting normal thyroid physiology.
Potentially relevant systems include:
An oxidative-stress-related genetic variant does not automatically cause low T3.
A more plausible genetic model is that thyroid activation may have less reserve when several supporting pathways are under pressure simultaneously.
T3 patterns may change with:
A lower T3 result in this setting may reflect broader physiological reserve rather than one broken conversion pathway.
Levothyroxine supplies synthetic T4.
The body must then convert some of that T4 into T3.
Some people taking levothyroxine have:
This has created interest in whether some treated patients generate less T3 from T4 alone.
The issue remains complex.
Possible explanations for persistent symptoms include:
A relatively low T3 while taking levothyroxine does not prove that persistent symptoms are caused by conversion.
TSH reflects pituitary exposure to thyroid hormone and feedback regulation.
It is highly useful for diagnosing and monitoring typical primary hypothyroidism.
But TSH does not directly measure:
This creates a real scientific question about tissue-specific thyroid physiology.
However:
The existence of tissue-specific biology does not mean persistent symptoms prove cellular hypothyroidism.
There is no routine clinical test that reliably demonstrates a clinically significant tissue-level conversion defect in a stable person with otherwise normal thyroid function.
A normal TSH and normal Free T4 therefore remain important evidence against untreated primary hypothyroidism even though they cannot describe every detail of tissue physiology.
Low T3 with normal TSH can occur during:
It does not automatically establish:
The broader review should include:
Reverse T3 is an inactive metabolite produced from T4.
It may rise during:
A higher reverse T3 can show that thyroid-hormone metabolism has changed.
It does not prove that reverse T3 is:
Reverse T3 should not be used by itself to diagnose:
In stable outpatients, TSH, Free T4, illness, nutrition, medication history, and overall clinical context are generally more informative.
Ratios involving T3 and reverse T3 are sometimes promoted as evidence of conversion failure.
They are not established routine diagnostic tools for hypothyroidism.
Limitations include:
A mathematical ratio can look precise without providing a validated diagnosis.
No.
Free T3 testing can be influenced by:
Total T3 may be useful in some clinical settings, but it is also influenced by hormone-binding proteins.
Neither should be interpreted without:
Tissue-specific thyroid activation may differ from circulating T3.
But there is no standard test that can demonstrate clinically important tissue hypothyroidism in a stable person with otherwise reassuring thyroid testing.
Symptoms cannot fill that diagnostic gap because thyroid-like symptoms are highly nonspecific.
Genetic modeling may identify lower inherited reserve.
That should generate a hypothesis to investigate—not establish a hidden diagnosis.
Common variants in DIO1 and DIO2 have been studied for possible effects on:
Research has not produced a simple genetic rule that can reliably guide treatment for an individual.
A common DIO1 or DIO2 variant does not prove:
The effect of one common variant is generally modest.
Its possible relevance increases when considered alongside:
Mutant treats DIO variants as reserve modifiers, not prescriptions.
The DIO2 Thr92Ala variant is frequently discussed in relation to persistent symptoms during levothyroxine treatment.
Research has investigated possible associations with:
Findings have not produced a reliable treatment rule.
Carrying the variant does not establish that someone:
It can be considered one signal within a larger thyroid-related susceptibility pattern.
It should not be used alone to select medication.
Rare pathogenic variants can substantially disrupt:
These disorders are different from the common susceptibility variants typically found in consumer genetic data.
They may involve:
A suspected rare thyroid-hormone disorder requires appropriate specialist evaluation and clinical-grade genetic interpretation.
It should not be inferred from a common SNP report.
Cells require:
Tissue-specific thyroid physiology is therefore real.
However, “cellular hypothyroidism” is often used online as a broad explanation for symptoms despite normal thyroid testing.
There is no routine validated test that proves a stable outpatient has clinically significant intracellular thyroid deficiency when TSH and Free T4 are normal.
A modeled tissue-level susceptibility can be useful as a health hypothesis.
It should not be presented as a confirmed medical diagnosis.
There is no single blood test that directly measures conversion capacity throughout the body.
Evaluation generally begins with the complete thyroid and clinical context.
Useful for screening and monitoring typical primary thyroid disease.
Provides information about circulating T4 supply.
May provide additional information in selected situations but should not be interpreted in isolation.
May help evaluate autoimmune thyroid disease when clinically relevant.
Depending on the pattern, evaluation may include:
This may become relevant when Free T4 is low but TSH is not appropriately elevated.
Depending on the clinical context, testing may involve:
Testing should follow the actual clinical question rather than a universal “conversion panel.”
Central hypothyroidism occurs when the pituitary or hypothalamus does not provide an appropriate thyroid signal.
A concerning pattern can involve:
Low Free T4 + Low, normal, or only mildly elevated TSH
This is primarily a thyroid-hormone supply and regulatory problem—not simply poor T4-to-T3 conversion.
It becomes more plausible with history such as:
Adrenal function may need assessment before thyroid hormone is started when central hypothyroidism is suspected.
Supplement marketing often presents conversion as a simple nutrient problem.
In reality, supplementation is most relevant when a genuine deficiency or inadequacy exists.
Potentially relevant nutrients include:
But more is not necessarily better.
Deiodinases depend on selenium.
Correcting true deficiency may be important.
Excess selenium can be harmful.
Iron is important for thyroid-hormone production and oxygen delivery.
Iron supplementation can also:
Iodine is required to produce thyroid hormone.
Excess iodine can worsen some thyroid disorders.
Zinc participates in many metabolic and signaling systems.
Deficiency should not be inferred from thyroid-like symptoms or genetics alone.
Adequate energy and amino-acid intake support overall metabolic and thyroid resilience.
No supplement can reliably correct low T3 caused by:
Liothyronine is synthetic T3.
It bypasses the need to convert that portion of thyroid hormone from T4 into T3.
That makes it biologically appealing when impaired conversion is suspected.
But treatment decisions are more complicated.
Clinical trials have not demonstrated a consistent overall benefit from combined T4/T3 treatment compared with levothyroxine alone across all patients.
Some individuals report meaningful improvement.
A carefully monitored trial may be considered by some clinicians in selected situations when:
A treatment decision should not be based solely on:
Liothyronine acts more rapidly than levothyroxine and can produce post-dose T3 peaks.
Potential adverse effects can include:
Risk can be more important in people with:
Treatment requires appropriate medical supervision.
Most standard liothyronine products are immediate release.
They can produce:
Compounded sustained-release T3 is sometimes used in an attempt to reduce those peaks.
However:
Sustained release does not remove the risks of excessive thyroid-hormone exposure.
The goal of thyroid treatment is not to produce the highest possible T3 result.
Excess thyroid signaling can cause:
Symptoms such as fatigue or brain fog can persist even while someone becomes biochemically overtreated.
Increasing T3 until every nonspecific symptom disappears is not a safe treatment strategy.
Lower effective thyroid signaling can reduce gastrointestinal movement.
A possible pathway is:
Lower effective thyroid signaling ↓ Slower stomach or intestinal movement ↓ Constipation and greater fermentation pressure ↓ More bloating and variable food tolerance
This may contribute to:
Gastrointestinal symptoms cannot prove that T4-to-T3 conversion is impaired.
Other causes of slow motility still need consideration.
A possible indirect sequence is:
Reduced effective thyroid signaling ↓ Slower gastrointestinal motility ↓ Greater fermentation and microbial pressure ↓ Greater demand on intestinal histamine handling ↓ Narrower histamine tolerance
This does not establish that conversion problems cause histamine intolerance.
Histamine-related symptoms can also involve:
Thyroid signaling may be one contributing biological pressure within a larger pattern.
Record:
Do not rely only on labels such as:
Conversion cannot compensate for inadequate T4 supply.
Relevant context includes:
Ask whether testing occurred during:
A thyroid panel obtained after recovery may look different.
Consider:
Under-eating is an important potential explanation for low T3.
Include:
Do not change prescribed treatment based solely on a conversion hypothesis.
Depending on the symptoms, relevant evaluation may include:
DIO1-, DIO2-, transporter-, receptor-, selenium-, and antioxidant-related genetic patterns can help describe inherited reserve.
They cannot determine:
Genetics can influence several stages of thyroid-hormone physiology.
DIO1 and DIO2 may influence circulating and tissue-level T3 production.
DIO3 contributes to how thyroid hormones are inactivated.
Deiodinases depend on selenium incorporation and broader selenoprotein biology.
Glutathione, thioredoxin, vitamin C transport, and related pathways may influence resilience within redox-sensitive systems.
Transport proteins help T4 and T3 enter cells.
Thyroid receptors and regulatory proteins influence cellular response after hormone enters the cell.
Pituitary and thyroid-related signaling influences how much T4 is available before conversion occurs.
Immune-checkpoint, thyroid-antigen, and antigen-presentation genetics may influence susceptibility to autoimmune thyroid activity.
This is important because autoimmune thyroid disease can affect thyroid-hormone supply.
But autoimmune susceptibility is not itself a T4-to-T3 conversion problem, and genetics cannot establish Hashimoto's disease, Graves disease, or active thyroid autoimmunity.
Illness, inflammation, under-eating, gut dysfunction, medication exposure, or metabolic stress may increase demand on an otherwise compensated thyroid system.
A more meaningful pattern may therefore look like:
Lower thyroid-activation reserve
+ greater redox demand
+ less supporting metabolic reserve
+ illness, inflammation, or inadequate energy availability
= less margin for maintaining T3 availability under stress
This describes susceptibility.
It does not prove that conversion is currently impaired.
Mutant does not treat one DIO2 variant as proof of a conversion disorder.
Instead, it evaluates several connected biological mechanisms.
Is enough T4 available to serve as substrate for T3 production?
Actual Free T4 and thyroid-treatment history matter much more than genetics alone for answering this question.
Do available genetic patterns suggest less reserve in pathways contributing to circulating T3 production?
A DIO1 finding alone does not establish clinically important conversion failure.
Do available genetic patterns suggest less reserve for tissue-level T3 generation?
Potential relevance may increase during:
This remains a susceptibility model—not a measurement of tissue T3.
Could illness, inflammation, or tissue stress alter pathways involved in thyroid-hormone inactivation?
Genetics alone cannot determine whether DIO3 activity is currently elevated.
Do selenium-related genetic patterns provide additional context around deiodinase reserve?
A genetic finding does not establish selenium deficiency.
Do glutathione-, thioredoxin-, vitamin C-, or related patterns suggest less resilience when oxidative demand increases?
These are supporting mechanisms rather than proof of thyroid dysfunction.
Do transporter-related genetic patterns suggest potentially different inherited transport reserve?
They do not establish cellular hormone deficiency.
Do receptor or regulatory patterns contribute to a hypothesis involving lower cellular thyroid-response reserve?
Common variants should not be interpreted as evidence of rare thyroid-hormone resistance.
Do genetic patterns involving pituitary or thyroid regulation suggest a different inherited set point or lower regulatory reserve?
Actual TSH and Free T4 remain essential for evaluating current thyroid function.
Could another biological system make a thyroid-related susceptibility more noticeable?
Examples may include:
Mutant then ranks cellular T3 activation alongside other thyroid and non-thyroid health hypotheses.
The result is not a diagnosis of conversion failure and not a prescription for liothyronine.
It is a structured health hypothesis that can be tested against real-world health information.
Genetics alone cannot tell you why T3 is low—or whether thyroid-hormone activation is relevant to your symptoms.
That is where Health Context becomes important.
For a cellular T3 activation hypothesis, useful context may include:
Mutant can identify information that may:
For example, a cellular T3 activation hypothesis may become more interesting when compatible genetic evidence occurs alongside a persistent thyroid pattern that cannot be readily explained by illness, under-eating, medication effects, or inadequate T4 supply.
It may become less compelling when:
The goal is not to make Health Context conform to the genetics.
It is to use Health Context to challenge the hypothesis.
This is an important part of the Mutant approach.
Suppose genetics suggest lower DIO2-related activation reserve.
That does not mean every future episode of fatigue, constipation, or brain fog should be explained by DIO2.
The hypothesis may weaken when:
A useful genetic analysis should be able to conclude:
“The genetic susceptibility exists, but it may not be particularly relevant to the current health question.”
Mutant structures thyroid-related genetics so the findings can be explored alongside:
Health Context can help AI explore questions such as:
AI can help compare evidence.
It does not establish a diagnosis simply because genetics and symptoms appear to align.
Mutant evaluates cellular T3 activation as part of your overall biological-systems analysis.
Your free analysis includes:
Your top 3 hypotheses may come from any biological system or hub.
A cellular T3 activation or other thyroid-related hypothesis is included in full only if it ranks among your top 3 overall findings.
No credit card required.
Mutant Full unlocks all remaining findings available from your analysis.
Included:
You can start free and upgrade at any time.
Mutant Free does not use a smaller thyroid analysis.
The same underlying analysis framework generates your findings.
Your top 3 ranked health hypotheses are completely unlocked.
All remaining ranked hypotheses are also unlocked.
There is no separate “free thyroid hub.”
Mutant supports compatible genetic data from:
All supported DNA sources use the same Mutant analysis framework.
What changes is genetic coverage.
Consumer DNA data may provide useful common markers involving:
Some markers used by Mutant may not be available.
A missing marker is treated as:
Missing data
not:
Normal
and not:
No risk
Whole-genome sequencing generally provides broader genetic coverage.
More genetic data should not simply make a cellular T3 hypothesis stronger.
Broader coverage can:
The purpose of broader DNA coverage is to improve evidence completeness.
Mutant does not upload or store your complete raw DNA file.
When you select compatible genetic data:
Arrange prompt medical evaluation for:
Seek emergency care for severe chest pain, fainting, significant breathing difficulty, profound confusion, or another acute medical emergency.
It generally refers to reduced generation of active T3 from T4.
Possible contributors include:
The phrase does not describe one single disease.
There is no single routine test that directly measures T4-to-T3 conversion in every tissue.
TSH, Free T4, T3, illness, nutrition, medications, treatment status, and symptoms need to be interpreted together.
No.
Low T3 can occur during:
Yes.
This can occur during:
No.
Reverse T3 frequently changes during illness and calorie deprivation.
It is not a validated standalone test for chronic conversion failure.
It is not an established routine diagnostic test for hypothyroidism or tissue-level thyroid deficiency.
Common DIO2 variants may modestly influence thyroid physiology.
They do not prove clinically significant conversion failure.
No.
The variant does not reliably determine whether someone will benefit from liothyronine.
No.
Genetics can identify susceptibility involving:
It cannot establish clinically significant intracellular thyroid-hormone deficiency.
Selenium is required by deiodinases.
Correcting true deficiency may matter.
Supplementing someone who already has adequate selenium may provide no benefit and can cause toxicity.
Yes.
Lower T3 can be part of the body’s adaptation to insufficient energy availability.
T3 may decline in some people, particularly when carbohydrate restriction also reduces total energy intake.
The clinical significance depends on the broader context.
Inflammatory illness can alter:
This does not establish a permanent conversion defect.
Some beta blockers at sufficiently high doses can reduce peripheral conversion.
The effect depends on the medication and dose.
Yes.
Some people taking levothyroxine have normal TSH with relatively lower serum T3.
This does not prove that persistent symptoms are caused by inadequate conversion.
Not based on symptoms, reverse T3, or genetics alone.
A clinician-supervised T3-containing treatment strategy may be considered in selected people with established hypothyroidism after broader evaluation.
Lower effective thyroid signaling can contribute to slower gastrointestinal motility.
Constipation also has many other possible causes.
Reduced thyroid signaling could contribute indirectly through slower gut motility and increased digestive pressure.
That pathway is plausible but does not diagnose histamine intolerance.
No.
Genetic susceptibility to autoimmune thyroid activity does not establish:
Clinical and laboratory context is required.
No.
Genetics can identify lower inherited reserve involving:
It cannot determine current thyroid-hormone status.
Yes.
Compatible 23andMe data can provide useful common thyroid-related markers.
Coverage varies by testing version.
Yes.
Compatible AncestryDNA data can also provide useful thyroid-related genetic coverage.
Some markers may be missing.
Whole-genome sequencing generally provides broader coverage of the genetic markers Mutant uses.
It does not change the type of Mutant analysis.
Free access is not assigned by hub.
Mutant Free includes your top 3 ranked health hypotheses across your entire analysis in full.
If a cellular T3 activation or other thyroid-related hypothesis ranks among your top 3, you can explore it completely with Mutant Free.
Other hypotheses remain visible in your ranked analysis, with complete details available through Mutant Full.
Mutant Full is $49/year and unlocks:
No.
The same underlying Mutant analysis framework generates your findings.
Free and Full determine how much of the resulting analysis you can open.
No.
Your complete raw DNA is read locally in your browser.
Only the genetic markers needed for the Mutant analysis are sent and retained.
No.
The questionnaire is optional.
It can add additional Health Context but is not required to generate your genetic analysis.
T4-to-T3 conversion matters.
But thyroid physiology should not be reduced to:
“Low T3 = broken DIO2 = take T3”
A more complete investigation asks:
Genetics can identify where this system may have less inherited reserve.
Health Context helps evaluate whether that susceptibility appears relevant to the person’s actual thyroid pattern.
Mutant organizes that evidence into ranked health hypotheses rather than assuming one genetic variant identifies the problem.
Your top 3 ranked health hypotheses are included in full with Mutant Free.
Mutant provides educational and informational genetic analysis. Its findings are health hypotheses, not diagnoses, and are not a substitute for medical evaluation, thyroid-function testing, clinical genetic testing, medication management, or treatment.